Effect of tirofiban hydrochloride in the treatment of coronary heart disease and its influence on homocysteine level
10.3760/cma.j.issn.1008-6706.2017.13.001
- VernacularTitle:盐酸替罗非班治疗冠心病的疗效及对同型半胱氨酸水平的影响
- Author:
Yin CHEN
;
Yumei YUAN
- Keywords:
Coronary artery disease;
Tirofiban hydrochloride;
Homocysteine;
C-reactive protein;
Fibrinogen
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(13):1921-1925
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of tirofiban hydrochloride in the treatment of coronary heart disease and its influence on homocysteine level.Methods 92 patients with coronary heart disease were selected as research subjects.They were randomly divided into the observation group and the control group,46 cases in each group.The control group was treated with anti-thrombotic,nitrates and other conventional western medicine.The observation group was treated with tirofiban hydrochloride based on the conventional treatment.Results The total effective rate of the observation group was 95.65%,which was higher than 82.61% of the control group,the difference was significant (χ2=4.039,P<0.05).And the homocysteine level in the observation group was (5.38±1.02)μmol/L,which was lower than (7.27±1.19)μmol/L in the control group,the difference was statistically significant (t=8.179,P<0.01).After treatment,the cardiac function CO level[(4.96±0.98)L/min],EF level[(62.48±11.16)%]and SV level[(86.37±11.47)mL]in the observation group were higher than those in the control group,the differences were statistically significant (t=2.271,2.954,2.911,all P<0.05).After treatment,the hs-CRP level[(4.25±1.32)mg/L]and Fib level[(3.14±0.73)g/L] in the observation group were lower than those in the control group,the differences were statistically significant (t=7.981,3.174,all P<0.01).ConclusionTirofiban hydrochloride in the treatment of coronary heart disease can effectively contribute to the reduction of homocysteine levels and alleviate atherosclerosis lesion progression,not only can reduce severity of myocardial ischemia and fibrinogen and high-sensitivity C-reactive protein levels,but also can reduce the thrombosis and inflammation produced by the degree of harm to the patients.
